Based on global climate models, ragweed distribution may expand in the northeastern United States.
The highest rates of active disease were seen for children aged 0 to 17 years and older adults aged 75 to 99 years.
The generic version of the EpiPen Jr (epinephrine injection, USP) 0.15mg as well as additional supply of the generic version of the EpiPen Auto-Injector 0.3mg will be made available in 2019.
Significant reduction in attack rate compared with placebo seen for 3 dose regimens of lanadelumab.
Clinicians are gaining a better understanding of how asthma and allergies are regulated by the circadian clock, which will help patients better alleviate their symptoms.
Consistent associations were observed per 5 mm Hg higher maternal blood pressures in early pregnancy with lower FEV1/FVC.
The most prevalent allergens are peanut, milk, shellfish, and tree nut.
The epinephrine autoinjector incremental cost-effectiveness ratio was $2,742,697 per quality-adjusted life-year at a market cost of $715 per twin pack.
Of the children with food allergy, 53% of infants have milk allergy vs 15% of teenagers.
More than 67% of patients who received AR101 were able to ingest a dose of 600 mg or more of peanut protein at the exit food challenge, without dose-limiting symptoms
Patients with both asthma and allergies had a significant increase in the number of prescriptions dispensed for controller medications.
Patients who received olopatadine/mometasone either once or twice daily experienced significant improvements in their instantaneous Total Nasal Symptom Scores compared with placebo.
Treatment reinitiation after a short interruption was well tolerated in patients taking standardized quality house mite sublingual immunotherapy tablets.
Significantly greater reductions in the mean esophageal eosinophil counts occurred in patients who received the humanized anti-interleukin 13 antibody, RPC4046.
The prevalence of depression in patients with atopic dermatitis was higher than in those without atopic dermatitis.
Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.
GSP301 treatment was associated with a significant improvement in reflective and instantaneous Total Nasal Symptom Scores compared with placebo.
Patients who received a fixed-dose combination nasal spray showed significantly improved Physician-assessed Nasal Symptom Scores compared with those who received placebo.
The FDA has approved the use of Oralair for the treatment of grass pollen-induced allergic rhinitis in pediatric patients aged 5-9.
Adverse drug reactions from the 300IR 5-grass pollen tablet occurred in approximately half of patients but typically resolved within a week of treatment.